Industry News


Ophthalmology, the specialty on the move. 

November 2015

Pfizer and Allergan are joining in the biggest buyout of the year, a $160 billion stock deal that will create the world's largest drug maker.

Link for more information:

ALPHAEON Corporation today announced the execution of a definitive agreement to acquire substantially all the assets of LENSAR, Inc., a leading global developer and manufacturer of Femtosecond Lasers Systems (FLS), through a wholly owned subsidiary.  The transaction is valued at up to $59 million in cash, stock and assumed debt. The transaction is subject to the completion of certain closing conditions on or before December 31, 2015. 

Link for more information:

October 2015

Shire announced topline results from OPUS-3, a phase 3 efficacy and safety study of the company’s lead drug candidate, lifitegrast. The company says the new data puts the dry eye drug candidate back on track for a commercial launch in 2016.

The OPUS-3 data comes just a week after the FDA formally declined the new drug application for Lifitegrast, requesting further clinical tests along with more information about product quality. Shire plans to use the OPUS-3 data as part of the resubmission of the new drug application for lifitegrast for the treatment of signs and symptoms for dry eye disease in the first quarter of 2016, with a potential launch later in 2016.

Link for more information:


May 2015 

Alcon Study Reveals Nearly Half of Americans Would Avoid Reading Glasses If They Knew It Made Them Look Older.  Click link to view

April 2015 

Alcon - Alcon intraocular lens gets FDA's stringent PMA approval.  Click link to view

Omeros - European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721.  Click link to view


SHIRE - U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults.  Click link to view

March 2015

Allergan - Actavis Completes Allergan Acquisition.  Click link to view

February 2015

Allergan - What to expect from Actavis-Allergan merger: CEO. Click link to view